Cargando…

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.

The dose limiting toxicities of the short infusion trial of the dacarbazine analog, CB10-277, were nausea and vomiting which appeared to be related to the peak plasma level of the parent drug. In addition, based on mouse studies, these dose limiting toxicities occurred at a less than optimal level o...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, B. J., Newell, D. R., Gumbrell, L. A., Jenns, K. E., Calvert, A. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968159/
https://www.ncbi.nlm.nih.gov/pubmed/8431368

Ejemplares similares